SCHRÖDINGER, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.57 USD | -0.70% |
|
-1.90% | -48.07% |
| 05-13 | Ajax Therapeutics, Inc. announced that it has received $94.99996 million in funding from a group of investors | CI |
| 05-07 | Ansys Partners With Schrodinger to Accelerate Materials Development | MT |
Presenter SpeechMichael Ryskin (Analysts)Great. And we're going to kick off our next session. ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.
Sector
Software
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
18.7
USD
Average target price
36.5
USD
Spread / Average Target
+95.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -48.07% | 1.36B | |
| +20.35% | 3,352B | |
| +16.53% | 91.95B | |
| +13.95% | 85.41B | |
| +40.68% | 54.69B | |
| -19.57% | 49.57B | |
| +35.77% | 47.8B | |
| -28.13% | 43.59B | |
| +86.12% | 42.61B | |
| -1.60% | 27.83B |
- Stock Market
- Equities
- SDGR Stock
- News Schrödinger, Inc.
- Transcript : Schrödinger, Inc. Presents at Bank of America Securities 2021 Tech Solutions for Drug Discovery Conference, Sep-20-2021 11
